Tracheobronchial Amyloidosis: Clinical Experience From 2018 to 2023 at a National Respiratory Centre
Respirology · 2026
DOI: 10.1002/resp.70144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respirology, 2026. Verfasst von Lynn Yim-Wah Shong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen Mary Hospital, Hong Kong, China. Hauptthemen laut MEDLINE: Amyloidosis, Bronchial Diseases, Tracheal Diseases. Die Arbeit nennt 33 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences, Excellence & Innovation Initiative of China-Japan Friendship Hospital, National High-Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Background and Objective Tracheobronchial amyloidosis is a rare disease. This study aimed to assess the clinical presentation, radiological findings, bronchoscopic features, pathological findings and management approach at a national respiratory centre in China.
Methods
We retrospectively analysed biopsy‐confirmed tracheobronchial amyloidosis cases from 2018 to 2023 using electronic medical records. Data on demographics, clinical manifestations, investigational findings, management and prognosis were analysed.
Results
Six patients (2 women and 4 men, mean age 55.5 years) were diagnosed with tracheobronchial amyloidosis. Common symptoms included cough, sputum and dyspnoea. None of the patients had evidence of extra‐pulmonary amyloidosis. Diagnosis was confirmed via tracheobronchial biopsy. Precursor proteins included AL‐λ and AL‐κ in 2 patients, AL‐κ and ATTR in one patient. The median delay from symptoms onset to diagnosis was 18 months while computerised tomography (CT) imaging expediated diagnosis of tracheobronchial amyloidosis, with a median time from CT thorax to diagnostic bronchoscopy of 2 days in four cases, with two cases lacking detailed information on the date of the initial CT. Treatments included bronchoscopic intervention in three patients and observation in three patients.
Conclusions
Patients with tracheobronchial amyloidosis often present with symptoms resembling those of other airway disorders. Considering this condition in differential diagnosis is crucial when standard treatments fail. Chest CT facilitates prompt referral for diagnostic bronchoscopy. No curative therapy is currently available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Queen Mary Hospital, Hong Kong, China.
- Department of Pulmonary and Critical Care Medicine, Centre of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
- Department of Pathology, China-Japan Friendship Hospital, Beijing, China.
- Department of Medicine, The University of Hong Kong, Hong Kong, China.
ORCID-Profile: Lynn Yim-Wah Shong, Gang Hou
Förderung
- CAMS Innovation Fund for Medical Sciences
- Excellence & Innovation Initiative of China-Japan Friendship Hospital
- National High-Level Hospital Clinical Research Funding
Zitieren
APA
Shong, L. Y., Zhou, G. W., Tong, R., Deng, M. M., Zhao, L., Fan, Z. P., Zheng, Z. W., Li, J., Lam, D. C., & Hou, G. (2026). Tracheobronchial Amyloidosis: Clinical Experience From 2018 to 2023 at a National Respiratory Centre. Respirology. https://doi.org/10.1002/resp.70144
Vancouver
Shong LY, Zhou GW, Tong R, Deng MM, Zhao L, Fan ZP, et al. Tracheobronchial Amyloidosis: Clinical Experience From 2018 to 2023 at a National Respiratory Centre. Respirology. 2026. doi:10.1002/resp.70144
BibTeX
@article{Shong2026,
author = {Shong, Lynn Yim-Wah and Zhou, Guo-Wu and Tong, Run and Deng, Ming-Ming and Zhao, Ling and Fan, Zhi-Ping and Zheng, Zi-Wen and Li, Jia and Lam, David Chi-Leung and Hou, Gang},
title = {Tracheobronchial Amyloidosis: Clinical Experience From 2018 to 2023 at a National Respiratory Centre},
journal = {Respirology},
year = {2026},
doi = {10.1002/resp.70144}
}
EUVIMED